Healthcare Industry News: Bard
News Release - June 7, 2007
Dr. Patrice Milos Joins Helicos BioSciences as Chief Scientific OfficerCAMBRIDGE, Mass.--(HSMN NewsFeed)--Helicos BioSciences Corporation (Nasdaq: HLCS ) announced today an addition to its leadership team. The Company has appointed renowned life sciences expert Dr. Patrice Milos as Vice-President and Chief Scientific Officer.
Dr. Milos joins Helicos from Pfizer Global Research and Development where she most recently held the position of Executive Director. An industry leader, Patrice joined Pfizer in 1993 where she held various research positions focusing on Pharmacogenomics and Molecular Sciences.
"Patrice's expertise and extensive experience within the life sciences is invaluable and will increase our company's ability to continue to develop innovative and breakthrough technology. Her role as Chief Scientific Officer will be critical to Helicos' continued growth" said Steve LomBardi, Chief Operating Officer of Helicos.
During her recent tenure as Executive Director, Molecular Profiling, Dr. Milos was responsible for leadership, strategic alignment and execution of the scientific disciplines of pharmacogenomics, proteomics, metabonomics and RNA profiling across the Pfizer portfolio from early discovery into the marketplace. She was pivotal in the establishment and oversight of key strategic investments in the genomics area, most notably, the Genetic Association Information Network, which is a partnership between the National Institutes of Health and several corporations including Pfizer.
"With the era of whole genome sequencing upon us, we are entering a time of unparalleled scientific opportunity in the understanding of human disease and drug response," said Dr. Milos. "Joining Helicos, an innovative company with vision and leadership in this field, will allow me to play an integral role in this scientific revolution. I am delighted to be joining such an outstanding group of accomplished professionals."
Dr. Milos is the author of numerous publications in the field of genomics and serves as a member of the National Advisory Council for Human Genome Research. She conducted post-doctoral research at Brown University and Harvard University, and earned her Master's and Ph.D. degrees at Rensselaer Polytechnic Institute in Troy, N.Y. She received her Bachelor of Arts from The College of Saint Rose in Albany.
About Helicos BioSciences
Helicos BioSciences Corporation is a life sciences company developing innovative genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. The company has developed its proprietary True Single Molecule Sequencing technology to enable ultra-high-throughput genetic analysis based on the direct sequencing of single molecules of nucleic acids. The company's corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800.
Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, Helicos' expectations concerning the prospective value of Dr. Milos' experience and expertise to Helicos and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Helicos' control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, our ability to successfully complete the manufacturing process and commercialize the HeliScope system; competition; changing technology and customer requirements; our ability to operate in an emerging market; market acceptance of our technology; our ability to retain our personnel and hire additional skilled personnel; our ability to manage our rapid growth and our ability to obtain capital when desired on favorable terms. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Helicos undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Helicos, see the disclosure contained in Helicos' public filings with the Securities and Exchange Commission.
Source: Helicos BioSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.